logo-loader
viewVitality Biopharma Inc

Vitality Biopharma CEO says cannabinoids have potential for neurological/inflammatory conditions

Vitality Biopharma (OTCQB:VBIO) CEO Robert Brooke tells Proactive Investors about the company's development of cannabinoid prodrug pharmaceuticals and how cannabinoids can be used for the treatment of serious neurological and inflammatory disorders.

Brooke says the cannabinoid prodrugs (known as cannabosides) can, upon ingestion, enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. This could be used by people with conditions such as Crohn's, IBS and colitis.

Brooke says cannabinoids also have the potential to be used as an alternative to opiate abuse.

Quick facts: Vitality Biopharma Inc

Price: 0.15 USD

OTCMKTS:VBIO
Market: OTCMKTS
Market Cap: $7.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Meteoric Resources hits more bonanza-grade gold at Juruena...

Meteoric Resources NL (ASX:MEI) managing director Andrew Tunks updates Proactive on more "thrilling" bonanza-grade drill results from the Juruena Gold Project in Brazil, following similar earlier results from the maiden drill program. Latest assays have returned up to 14 metres at 81.7 g/t...

in 8 hours, 5 minutes

2 min read